Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

192
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
192
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

263
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
263
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
134
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

459
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
459
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

834
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
834

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Klebsiella genus as driver of human disease: from infections to non-communicable disorders.

Nature reviews. Microbiology·2026
Same author

IBDome: An Integrated Molecular, Histopathological, and Clinical Atlas of Inflammatory Bowel Diseases.

Gastroenterology·2026
Same author

Circulating Interleukin-37 as a Biomarker Candidate for Hepatocellular Carcinoma in Decompensated Advanced Chronic Liver Disease.

Life (Basel, Switzerland)·2026
Same author

Anti-TNF therapies in autoimmune hepatitis: Promises and challenges.

Journal of hepatology·2026
Same author

<i>Escherichia-Shigella</i> expansion and metabolite dysregulation in type 3c diabetes: linking microbiome alterations to exocrine pancreatic insufficiency.

Frontiers in endocrinology·2026
Same author

Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023.

eGastroenterology·2026

Related Experiment Video

Updated: Jul 12, 2025

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
10:21

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test

Published on: September 22, 2023

659

Does cardiovascular risk matter in IBD patients?

Herbert Tilg1, Mathurin Fumery2, Charlotte R H Hedin3,4

  • 1Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Innsbruck, Austria.

Journal of Internal Medicine
|October 29, 2023
PubMed
Summary

Inflammatory bowel disease (IBD) patients face increased cardiovascular and thromboembolic risks, especially with obesity and certain medications like Janus kinase (JAK) inhibitors and sphingosine 1-phosphate (S1P) receptor modulators. Regular cardiovascular risk assessment is crucial for IBD management.

Keywords:
IBDJanus kinase inhibitorscardiovascular risksphingosine 1 phosphate receptor modulators

More Related Videos

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

3.9K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K

Related Experiment Videos

Last Updated: Jul 12, 2025

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
10:21

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test

Published on: September 22, 2023

659
A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

3.9K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K

Area of Science:

  • Gastroenterology and Cardiology
  • Pharmacology and Therapeutics

Background:

  • Cardiovascular and thromboembolic risks are rising globally and impact inflammatory bowel disease (IBD) patients.
  • Obesity, a worldwide health concern, affects IBD populations and may have a causal link to Crohn's disease.
  • Active IBD itself elevates the risk of cardiovascular events like myocardial infarction and stroke.

Purpose of the Study:

  • To highlight the significant cardiovascular risks associated with IBD.
  • To detail the specific cardiovascular risks posed by Janus kinase (JAK) inhibitors and sphingosine 1-phosphate (S1P) receptor modulators used in IBD treatment.
  • To emphasize the need for vigilant cardiovascular risk assessment and management in IBD patients.

Main Methods:

  • Review of cardiovascular and thromboembolic risks in the general population and IBD patients.
  • Analysis of cardiovascular side effects associated with JAK inhibitors (e.g., tofacitinib) and S1P receptor modulators.
  • Discussion of risk factors including obesity, active IBD, and drug interactions.

Main Results:

  • JAK inhibitors can lead to hypertension, dyslipidemia (elevated LDL, triglycerides), and atherosclerosis.
  • S1P receptor modulators may cause transient bradycardia, AV block, QT interval prolongation, arrhythmias (e.g., Torsades de Pointes), and hypertension.
  • Cardiovascular events in IBD patients often occur in those with pre-existing risk factors.

Conclusions:

  • IBD healthcare providers must proactively assess cardiovascular risk in patients.
  • Particular vigilance is required for patients on S1P modulators due to potential drug interactions and specific cardiac risks.
  • Ongoing cardiovascular risk assessment should be integrated into routine IBD care.